Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cuprina Holdings (Cayman)CUPR -2.51%10 EV-to-EBITDA is -2.62 as of Jul. 14, 2026. GuruFocus rates CUPR with a GF Score™ of 10/100. The stock has 6 warning signs investors should review. Among 511 Medical Devices & Instruments companies, Cuprina Holdings (Cayman) ranks worse than 195694.52% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cuprina Holdings (Cayman)'s enterprise value is $9.28 Mil.
Cuprina Holdings (Cayman)'s EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-3.54 Mil. Therefore, Cuprina Holdings (Cayman)'s EV-to-EBITDA for today is -2.62.
The historical rank and industry rank for Cuprina Holdings (Cayman)'s EV-to-EBITDA or its related term are showing as below:
CUPR'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -168.89 Med: -13.7 Max: -0.88
Current: -2.62
During the past 5 years, the highest EV-to-EBITDA of Cuprina Holdings (Cayman) was -0.88. The lowest was -168.89. And the median was -13.70.
CUPR's EV-to-EBITDA is ranked worse than 100% of 511
companies
in the Medical Devices & Instruments industry
Industry Median: 14.2
vs CUPR: -2.62
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cuprina Holdings (Cayman)'s PE Ratio (TTM) for today is calculated as:
Cuprina Holdings (Cayman)'s share price for today is $4.2212.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cuprina Holdings (Cayman)'s Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-1.420.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Cuprina Holdings (Cayman)'s EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cuprina Holdings (Cayman) EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cuprina Holdings (Cayman)'s EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cuprina Holdings (Cayman)'s EV-to-EBITDA falls into.
Cuprina Holdings (Cayman)'s current Enterprise Value is $9.28 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cuprina Holdings (Cayman)'s EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-3.54 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cuprina Holdings (Cayman) (CUPR) has a EV-to-EBITDA of -2.62 as of Jul. 14, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cuprina Holdings (Cayman). According to the industry distribution chart, Cuprina Holdings (Cayman) ranks #999999 out of 511 companies in the Medical Devices & Instruments industry.
Is Cuprina Holdings (Cayman)'s EV-to-EBITDA too high?
Cuprina Holdings (Cayman)'s current EV-to-EBITDA is -2.62. Based on the distribution chart, Cuprina Holdings (Cayman) ranks #999999 out of 511 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Cuprina Holdings (Cayman) has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Cuprina Holdings (Cayman)'s EV-to-EBITDA compare to BNGO and UEEC?
According to the Medical Devices & Instruments industry distribution chart, Cuprina Holdings (Cayman) ranks #999999 out of 511 companies for EV-to-EBITDA. This places Cuprina Holdings (Cayman) in the lower half of its industry. The industry median EV-to-EBITDA is 14.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.20, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cuprina Holdings (Cayman). For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cuprina Holdings (Cayman)'s current EV-to-EBITDA is -2.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cuprina Holdings (Cayman) stock overvalued right now?
Cuprina Holdings (Cayman) (CUPR) has a current EV-to-EBITDA of -2.62. The current EV-to-EBITDA is -2.62. Cuprina Holdings (Cayman)'s overall GF Score™ is 10/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Cuprina Holdings (Cayman) (CUPR), the current EV-to-EBITDA is -2.62 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cuprina Holdings (Cayman) Ltd is a biomedical and biotechnology company that is dedicated to the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sector. It manufactured and distributed a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as Maggot Debridement Therapy, or MDT, which is an effective alternative to surgical debridement.
10GF Score
Get the complete analysis for CUPR
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CUPR has been successfully added to your 
